Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 9/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYBB | P04839 | 1/20 | 0.40 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19576173 | 0.90 | GBA1 (0.49) | NOTUMDPP4NCF1P2RX7LGALS3 | |
| SCHEMBL19576221 | 0.90 | NOTUM (0.42) | NOTUMDPP4NCF1P2RX7LGALS3 | |
| SCHEMBL19576157 | 0.90 | GBA1 (0.49) | NOTUMDPP4NCF1P2RX7LGALS3 | |
| SCHEMBL19576220 | 0.90 | NOTUM (0.42) | NOTUMDPP4NCF1P2RX7LGALS3 | |
| SCHEMBL19576228 | 0.90 | NOTUM (0.42) | NOTUMDPP4NCF1P2RX7LGALS3 | |
| SCHEMBL19576084 | 0.90 | GBA1 (0.49) | NOTUMDPP4NCF1P2RX7LGALS3 | |
| SCHEMBL21643807 | 0.90 | DPP4 (0.44) | NOTUMDPP4NCF1P2RX7LGALS3 | |
| SCHEMBL19576085 | 0.90 | NOTUM (0.42) | NOTUMDPP4NCF1P2RX7LGALS3 | |
| SCHEMBL16450528 | 0.89 | NOTUM (0.41) | NOTUMDPP4NCF1P2RX7LGALS3 | |
| SCHEMBL19576264 | 0.86 | NOTUM (0.39) | NOTUMDPP4NCF1P2RX7LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238322-A1 | THERAPEUTIC AGENTS AND METHODS OF PRODUCING SAME | Glycosynnovations Pty Ltd (AU) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238322-A1 | THERAPEUTIC AGENTS AND METHODS OF PRODUCING SAME | SIGLEC7, FUT5, UGCG | NOTUM 483/4885DPP4 471/4885NCF1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.